Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 210

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 210
---
 Our ability to enforce protect our intellectual property rights along
    with the potential of future legal proceedings filed against us claiming intellectual property infringement

    ●
    Retention, recruitment, and training of senior management and key personnel

Risks Related to Product Development, Regulatory
Approval, Manufacturing and Commercialization 

    ●
    We may not be able to develop commercial products despite significant
    investments in R&D

    ●
    Our branded products and product candidates in development cannot be
    sold without regulatory approval

    ●
    Our drug candidates may face competition sooner than we expect

    ●
    We rely on third parties to manufacture and conduct clinical trials
    of our branded drug products and product candidates

    ●
    We may not be successful in obtaining market exclusivity for our product
    candidates

Risks Related to Our Indebtedness 

    ●
    Our ability to pay the interest and debt service payments associated
    with the Notes

    ●
    The Notes are unsecured, effectively subordinated to any secured indebtedness,
    with limited protection for holders of the Notes

    ●
    The Notes are subject to various market factors, including market interest
    rates, trading activity, third-party ratings and other factors

Risks Related to Our Common Stock

    ●
    Volatility of the price of our common stock

    ●
    Our stock price falling as a result of future offerings or sales

You should carefully consider
the following risk factors in addition to the other information contained in this Annual Report. Our business, financial condition, results
of operations, and prices of our common stock and Notes could be materially adversely affected by any of these risks.

 20 

Risks Related to Economic Conditions and Operations
of Our Business. 

We may not be profitable in the future.

As of December 31, 2024, our
accumulated deficit was $(151,385,000). Our current projections indicate that we will have operating income and/or net income during
2025; however, these projections may not be correct and our plans could change. Also, we could incur increasing operating losses in the
foreseeable future for our commercialization activities, research and development, and our pharmaceutical compounding business, which
would impact net income. Although we have been generating revenue from our operations, our ability to generate the revenues necessary
to achieve and maintain profitability will depend on many factors, including those discussed in this “Risk Factors” section.
Our business plan and